Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer combo trial halted early – only 10 patients enrolled

NCT ID NCT06016270

Terminated Disease control Sponsor: STCube, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 26 times

Summary

This study tested a new drug (hSTC810) combined with chemotherapy (paclitaxel) in people with advanced small cell lung cancer that returned after initial treatment. The goal was to see if the combination is safe and shrinks tumors. Only 10 patients took part before the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Bundang Hospital

    Seoul, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, 16247, South Korea

  • Tisch Cancer Institute at Mount Sinai

    New York, New York, 10029, United States

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER EXTENSIVE-STAGE SMALL-CELL LUNG CANCER